Verona Pharma plc
Disclosed SEC business address
3 MORE LONDON RIVERSIDE, LONDON, X0, SE1 2RE
Verona Pharma plc (ticker CIK0001657312, CIK 0001657312) is tracked by Global Barry from its public SEC filings and disclosures. Disclosed industry classification: Pharmaceutical Preparations (SIC 2834). Disclosed business address country: United Kingdom. Every item is grounded on the cited public source — no figures are fabricated.
Full evidence detail
Company deep views this month: 1 of 5.
Filing intelligence
50 filings ingested; deep FILING ANALYSIS shown for 4 filings.
- FACT Only one ingested version of this accession exists; no intra-document revisions have been observed. Change tracking for this filing requires ≥2 ingested versions. 2025-10-07 source ↗
- ANALYSIS This 8-K was filed 13 days after the previous ingested 8-K (2025-09-24). 3 filings of this type are ingested. 2025-10-07 source ↗
- UNKNOWN Changed risk-factor language (Item 1A): not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2025-10-07 source ↗
- UNKNOWN MD&A highlights: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2025-10-07 source ↗
- UNKNOWN Material business developments: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2025-10-07 source ↗
- UNKNOWN Debt / capital-structure changes: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2025-10-07 source ↗
- UNKNOWN Acquisitions / divestitures: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2025-10-07 source ↗
- UNKNOWN Litigation / regulatory matters: not derivable from ingested evidence. Current ingestion retains filing metadata, XBRL financial facts, insider-ownership disclosures, and the issuer submission snapshot — not the full filing document body. This item would require ingesting the filing's primary document text. 2025-10-07 source ↗
Latest developments
Most recent SEC filing events ingested for this company (newest first).
- FACT SCHEDULE 13G filed 2025-11-14 source ↗
- FACT SCHEDULE 13G/A filed 2025-11-14 source ↗
- FACT SCHEDULE 13G/A filed 2025-11-14 source ↗
- FACT SCHEDULE 13G filed 2025-10-17 source ↗
- FACT 4 filed (period 2025-10-07) 2025-10-08 source ↗
- FACT 4 filed (period 2025-10-07) 2025-10-08 source ↗
- FACT 4 filed (period 2025-10-07) 2025-10-08 source ↗
- FACT 4 filed (period 2025-10-07) 2025-10-08 source ↗
- FACT 4 filed (period 2025-10-07) 2025-10-08 source ↗
- FACT 4 filed (period 2025-10-07) 2025-10-08 source ↗
Insider ownership filings
34 insider ownership filings (Forms 3/4/5) ingested (metadata level).
Geographic footprint (disclosed)
Geographic footprint limited to locations disclosed in ingested evidence.
- FACT Principal executive office (disclosed): LONDON, X0, SE1 2RE
- FACT Mailing address (disclosed): LONDON, X0, SE1 2RE
- FACT State/country of incorporation (disclosed): United Kingdom
Industry classification (disclosed)
Industry classification as disclosed by the issuer's SEC record.
- FACT Primary industry (disclosed SIC): Pharmaceutical Preparations (SIC 2834)
- FACT SEC filer category: Large accelerated filer
Supply chain
No supplier or customer relationships are disclosed in ingested evidence. Supply-chain relationships are shown only when explicitly disclosed and cited; undisclosed relationships are never inferred.
- UNKNOWN No supplier or customer relationships are disclosed in ingested evidence. Supply-chain relationships are shown only when explicitly disclosed and cited; undisclosed relationships are never inferred.
Risk factors
Risk-factor language requires ingested filing document bodies.
- UNKNOWN Risk-factor language requires ingested filing document bodies.
Sources
- U.S. Securities and Exchange Commission, EDGAR · XBRL company facts · retrieved 2026-10-24T10:17:10.005562+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-01T07:58:39.080423+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-01T07:58:43.249065+00:00
- U.S. Securities and Exchange Commission, EDGAR · filing document · retrieved 2026-11-01T07:58:36.804150+00:00
Grounded on public SEC filings and disclosures with explicit evidence tiers and citations. This page is informational only and is not investment advice. No figures are fabricated; unavailable data is shown as unavailable.